Icon Bioscience, Inc. Company Profile

16:32 EDT 19th March 2018 | BioPortfolio

Icon Bioscience, Inc., (IBI), is a privately held biopharmaceutical company that specializes in the development and commercialization of novel ophthalmic pharmaceuticals based on its Verisome(TM) drug delivery technology. IBI is developing a broad portfolio of clinically superior specialty pharmaceuticals targeting major ophthalmic indications including macular edema, glaucoma, age-related macular degeneration and cataract surgery inflammation. In addition to IBI-10090, which will begin pivotal clinical trials in the next few months, IBI-20089 has completed its initial clinical trial in patients with cystoid macular edema associated with retinal vein occlusion. It is designed to deliver triamcinolone for up to a year with a single intravitreal injection. IBI anticipates two more products will enter clinical trials in early 2011. IBI has also entered into agreements with multiple international pharmaceutical companies interested in the use of the Verisome technology for its own ophthalmic products. For more information please refer to

News Articles [350 Associated News Articles listed on BioPortfolio]

Icon Bioscience Receives FDA Approval for Dexycu (dexamethasone intraocular suspension) for Treating Inflammation Associated With Cataract Surgery

Newark, CA (February 12, 2018) – Icon Bioscience, Inc. (IBI), a specialty biopharmaceutical company focused on utilizing its Verisome® drug-delivery platform to develop unique intraocular eye-care ...

FDA approves Dexycu to treat cataract surgery inflammation

Icon Bioscience reported the FDA approved its new drug application for Dexycu, a dropless therapeutic designed to treat inflammation associated with cataract surgery.The current standard treatment aft...

FDA approves Icon Bioscience's Dexycu

Recent Research Analysts' Ratings Updates for Icon

Several brokerages have updated their recommendations and price targets on shares of Icon in the last few weeks: 1/24/2018 - Icon was given a new $109.00 price target on by analysts at Mizuho. They no...

ICON and the International Consortium for Health Outcomes Measurement Unveil the World’s ...

ICON Media ContactDeena MistryWeber Shandwick+44 (0)207 067

MediMedia Managed Markets, an ICON Company, Wins Two Gold Industry Awards for Data Analytics ...

ICON Press Office EnquiriesWeber ShandwickOlivia PimentaEmail:

Analysts' Recent Ratings Updates for Icon

They now have a $131.00 price target on the stock. 2/15/2018 - Icon had its "neutral" rating reaffirmed by analysts at Mizuho.

Investment Analysts' Weekly Ratings Updates for Icon Plc

They now have a $120.00 price target on the stock, up previously from $105.00. 10/12/2017 - Icon Plc had its "buy" rating reaffirmed by analysts at Robert W. Baird.

PubMed Articles [77 Associated PubMed Articles listed on BioPortfolio]

Accelerating electron tomography reconstruction algorithm ICON with GPU.

Electron tomography (ET) plays an important role in studying in situ cell ultrastructure in three-dimensional space. Due to limited tilt angles, ET reconstruction always suffers from the "missing wedg...

Icon arrays help younger children's proportional reasoning.

We investigated the effects of two context variables, presentation format (icon arrays or numerical frequencies) and time limitation (limited or unlimited time), on the proportional reasoning abilitie...

Randomized Cross-over Comparison of Icon™ Reusable Underwear to Disposable Pads for the Management of Mild to Moderate Urinary Incontinence.

The objective of this study was to compare disposable pads to Icon™ reusable underwear for the management of urinary incontinence on dimensions of quality of life and product performance.

Irrational choice behavior in human and nonhuman primates.

Choice behavior in humans has motivated a large body of research with a focus on whether decisions can be considered to be rational. In general, humans prefer having choice, as do a number of other sp...

Nursing students collaborating to develop multiple-choice exam revision questions: A student engagement study.

Nursing students find bioscience subjects challenging. Bioscience exams pose particular concerns for these students, which may lead to students adopting a surface-approach to learning.

Clinical Trials [12 Associated Clinical Trials listed on BioPortfolio]

The Effect of ICON Treatment on WPL With Patients After Fixed Orthodontic Appliances

The aim of this study is to determine the effect of ICON on White spot lesions compared to CPP-ACPF plus.

Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)

The purpose of this study is to evaluate the safety and effects of repeated intravitreal injections of ICON-1 0.6 mg administered as maintenance therapy or in combination with aflibercept ...

Randomized Controlled Crossover Comparison of Icon Underwear to Disposable Pads

This is a randomized cross over trial to compare quality of life and product performance between Icon reusable underwear versus standard disposable pad in patients with mild to moderate ur...

Evaluation of 3-V Bioscience-2640 to Reduce de Novo Lipogenesis in Subjects With Characteristics of Metabolic Syndrome

Metabolic syndrome increases the risk for development of heart disease. Another condition associated with metabolic syndrome is fatty liver disease which is also referred to as nonalcoholi...

Non-invasive Monitor in Endoscopic Invasive Procedure

We include the patients who need painless invasive endoscopic precedure, we collect the dempgraphic data and apply the non-invasive device ICON on patients during the who procedure.

Companies [330 Associated Companies listed on BioPortfolio]

Icon Bioscience Inc.

Icon Bioscience, Inc. is a privately held specialty biopharmaceutical company focused on the development and commercialization of unique ophthalmic pharmaceuticals based on its pa...

Icon Bioscience, Inc.

Icon Bioscience, Inc., (IBI), is a privately held biopharmaceutical company that specializes in the development and commercialization of novel ophthalmic pharmaceuticals based on its Verisome(TM) drug...

ICON Clinical Research

ICON was founded in 1990 by a group of experienced professionals, who were dedicated to providing the pharmaceutical and biotechnology industries with exceptional clinical research and biometric servi...

ICON Eyecare

ICON Eyecare is a leading surgical and medical eye care provider, based out of Denver, CO. Since 1999, ICON has been building a Center of Ophthalmology Excellence empowered by an ...

ICON plc

ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company specialises in the strategic devel...

More Information about "Icon Bioscience, Inc." on BioPortfolio

We have published hundreds of Icon Bioscience, Inc. news stories on BioPortfolio along with dozens of Icon Bioscience, Inc. Clinical Trials and PubMed Articles about Icon Bioscience, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Icon Bioscience, Inc. Companies in our database. You can also find out about relevant Icon Bioscience, Inc. Drugs and Medications on this site too.

Quick Search


Relevant Topics

Bioscience - any of the sciences that deal with living organisms.  The study of the nature, behavior, and uses of living organisms as applied to biology. Any of the branches of natural science dealing with living things, such as their structure, b...

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Corporate Database Quicklinks

Searches Linking to this Company Record